This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

🎙️ What does the future hold for people living with NMOSD and MOGAD? With new treatments emerging and research advancing, there are important reasons for hope.

As part of Patient Community Day 2026, we're pleased to share the second episode in our two-part ECTRIMS Podcast series, exploring the latest research and the perspectives of people living with MS and related neurological conditions.

Host Brett Drummond sits down with Taylor Ann Macy, Director of Patient Engagement at the Sumaira Foundation who lives with NMOSD, and Dr Eoin Flanagan, Professor of Neurology at Mayo Clinic, for a conversation about scientific progress, lived experience and the importance of bringing patients and researchers together.

• What are the challenges of living with a rare neuroimmune condition?
• How are new treatments changing the outlook for NMOSD and MOGAD?
• And why are patient voices and community connections so important in shaping future research?

From the isolation that can come with a rare diagnosis to the growing optimism around treatment and research, this conversation highlights both the challenges and the possibilities ahead.

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

What does the MS community need from research – and how can we make sure the voices of people living with MS help shape what comes next?

As part of Patient Community Day 2026, we're sharing a special collaborative episode from RealTalk MS and the ECTRIMS Podcast, hosted by Jon Strum.

Jon is joined by Karen Jacoby, MS advocate and person living with MS, and Peter Feys, Professor of Rehabilitation Sciences and Neurorehabilitation at Hasselt University – for a conversation that puts the patient perspective at the centre – exploring the relationship between research, lived experience and the priorities that matter to people affected by MS.

Recorded at Patient Community Day in Toronto, the episode forms part of the wider conversations taking place during the 10th Joint ACTRIMS-ECTRIMS Meeting – but this one is specifically for, and about, the MS community.

This episode was produced and hosted by RealTalk MS – a Supporting Partner of Patient Community Day – and is being shared across ECTRIMS channels with permission from Jon Strum to help the conversation reach as many people as possible.

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Three days of science, debate and discovery.

For the final episode in our special MSToronto2026 podcast series, ECTRIMS Executive Committee member Jaume Sastre-Garriga joins host Brett Drummond direct from Toronto.

Together, they unpack the key insights from Day Three, including the Late Breaking Abstract session, before stepping back to reflect on the Joint Meeting as a whole.

What stood out across the week? Which developments and conversations could have lasting significance? And as thousands of researchers and clinicians prepare to leave Toronto, what comes next for the MS field?

Recorded at the 10th Joint ACTRIMS-ECTRIMS Meeting, this is our final dispatch from Toronto – bringing together the science, conversations and ideas that shaped an extraordinary week.

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Today, our special podcast series brings together two major voices from the North American MS community:

• Tim Coetzee, National Multiple Sclerosis Society
• Pamela Valentine, MS Canada

Scientific progress in MS is accelerating. But is that progress reaching the people who need it?

Alongside their reflections on the key takeaways and conversations from Day Two of MSToronto2026, Tim and Pamela join host Brett Drummond to look beyond individual studies and ask some bigger questions about where the MS field goes next.

Where does the MS community need progress most urgently? How can researchers, clinicians, patient organisations and people affected by MS work together more effectively? And how do we make sure scientific advances ultimately translate into meaningful change in people's lives?

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Day One at MSToronto2026 – and we're taking you inside one of the meeting's headline lectures.

Our special MSToronto2026 podcast series continues with Daniel Reich – the MSToronto2026 Lecturer – as he joins host Brett Drummond to reflect on some of the key takeaways from the first full day in Toronto.

Then, we go deeper. What if imaging could help us connect the dots in MS - from disease mechanisms to networks to the person living with MS?

Fresh from his lecture, Unifying Multiple Sclerosis: Imaging from Teams to Tissue to Biology, Daniel takes the conversation beyond the stage:

· What can imaging reveal about the biology driving MS?

· How is it changing the way we understand what is happening in the brain?

· And where could the next generation of imaging take MS research?

Recorded direct from Toronto, our MSToronto2026 series is only getting started. Follow the ECTRIMS Podcast as we bring you new conversations and highlights direct from Toronto throughout the Joint Meeting.

---

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

The ECTRIMS Podcast is on the ground at MSToronto2026 – bringing you the conversations, insights and highlights as they happen.

Kicking off our special MSToronto2026 Joint Meeting Series, Ann Yeh joins host Brett Drummond direct from Toronto to unpack the highlights of Pre-Day.

Before the 10th Joint ACTRIMS-ECTRIMS Meeting officially begins, Pre-Day puts the spotlight on paediatric MS and related neuroinflammatory diseases – and some of the important questions shaping the field right now.

What stood out? What should clinicians and researchers take away? And which conversations are already setting the stage for the meeting ahead?

🎙️ This is just the beginning. Listen now, and follow the ECTRIMS Podcast throughout MSToronto2026 as we bring you new episodes direct from Toronto across the week.

---

LAND ACKNOWLEDGEMENT

Patient Community Day takes place in Toronto, Canada, on the traditional territory of many nations, including the Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee and the Wendat peoples. Toronto is now home to many diverse First Nations, Inuit and Métis peoples. We also acknowledge that Toronto is covered by Treaty 13 with the Mississaugas of the Credit.

---

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Can clinicians identify MS progression as it happens, or does confirming meaningful disability worsening require months of observation?

Early recognition of multiple sclerosis (MS) progression is critical to informing clinical decisions. Yet distinguishing genuine disease progression from temporary fluctuations remains one of the challenges in routine MS care.

In this episode of the ECTRIMS Podcast, produced in collaboration with the Multiple Sclerosis Journal, host Associate Professor Anneke van der Walt is joined by Professor Helmut Butzkueven (Monash University, Australia) and Professor Tjalf Ziemssen (University Hospital Dresden, Germany) to explore both sides of a timely clinical controversy: Can we detect a progression event in an MS clinic in real time?

Drawing on opposing perspectives published in the Multiple Sclerosis Journal, the discussion examines the value and limitations of disability assessments, longitudinal patient registries, digital monitoring tools and patient-reported changes.

Can routinely collected clinical data help clinicians recognise progression earlier? How reliable are current measures such as the Expanded Disability Status Scale (EDSS)? And what can clinicians do to identify meaningful change when consultation time and resources are limited?

The conversation highlights the importance of balancing early recognition with diagnostic certainty, while keeping the patient's lived experience central to clinical assessment.

Read the accompanying publications in the Multiple Sclerosis Journal:

• YES – Can we detect a progression event in an MS clinic in real time? https://journals.sagepub.com/doi/full/10.1177/13524585251409568
• NO – Can we detect a progression event in an MS clinic in real time?https://journals.sagepub.com/doi/full/10.1177/13524585251409547
• Accompanying commentary https://journals.sagepub.com/doi/full/10.1177/13524585251409579

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.